In January 2020, MyBiotech GmbH, a start-up company in the biotech industry, and MJR PharmJet GmbH, experts in pharmaceutical development joined forces and will further expand their activities in biotech and pharma.
The merger will not remain the only major change in Überherrn. From 2020, own products will be developed and manufactured on site. The focus is on green technologies, e.g. for the sustainable production of omega-3 fatty acids from algae. The manufacturing of innovative, more efficient pharmaceuticals will also be tackled: “Production in the pharmaceutical sector will take place under strict regulations according to GMP. The combination of biotechnology and pharmaceutical development is unique in this form, and will help MyBiotech to further grow and expand.", said Dr. Emre Türeli, CSO of MyBiotech.